Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper
Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...
ENDPOINTS NEWS11d
No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment
Novartis CEO Vas Narasimhan assured investors on Tuesday that it takes a careful, systematic approach to M&A after recording ...
European stocks close lower; HSBC gains 4% on earnings beat; Lufthansa falls
European markets closed lower Tuesday as traders in the region continued to digest the latest slew of earnings reports.
Swissinfo7d
Novartis CEO: ‘Our strategy is bearing fruit’
Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.
FiercePharma11d
Novartis' Scemblix leaps into newly diagnosed leukemia—where winning over doctors may take time
Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an ...
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript
Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...
Yahoo Finance7d
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper
ZURICH (Reuters) - Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant ...